The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Chiesi (I)
Consulting or Advisory Role - Merck
LITESPARK-004 (MK-6482-004) phase 2 study of belzutifan, an oral hypoxia-inducible factor 2α inhibitor (HIF-2α), for von Hippel-Lindau (VHL) disease: Update with more than two years of follow-up data.
 
Eric Jonasch
Consulting or Advisory Role - aravive; Aveo; Calithera Biosciences; Eisai; Exelixis; Merck; NiKang Therapeutics; Novartis; Pfizer; Takeda
Research Funding - Arrowhead Pharmaceuticals (Inst); Merck; NiKang Therapeutics; Novartis
Travel, Accommodations, Expenses - Pfizer
 
Othon Iliopoulos
No Relationships to Disclose
 
Wendy Kimryn Rathmell
Stock and Other Ownership Interests - Caribou Biosciences (I); Nirogy Therapeutics (I); Sitryx (I)
Consulting or Advisory Role - Caribou Biosciences (I); Nirojy (I); Sitryx (I)
Research Funding - Incyte (I); Peloton Therapeutics (Inst); Sitryx (I)
Patents, Royalties, Other Intellectual Property - ClearCode34 Risk prediction biomarker for kidney cancer; hERV 3-2 expression as a biomarker of response to immunotherapy
 
Vivek Narayan
Honoraria - Pfizer
Consulting or Advisory Role - Amgen; AstraZeneca; Exelixis; Janssen Oncology; Merck; Myovant Sciences; Pfizer/EMD Serono; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Tmunity Therapeutics, Inc. (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Stephane Oudard
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; IPSEN; Janssen; Merck; MSD Oncology; MSD Oncology; Novartis; Pfizer; Roche; Roche; Sanofi
Research Funding - Ipsen; Sanofi
Travel, Accommodations, Expenses - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Merck; MSD Oncology; Novartis; Pfizer; Roche
 
Tobias Else
Consulting or Advisory Role - Corcept Therapeutics; HRA Pharma; Merck; Progenics
Research Funding - Corcept Therapeutics; Merck; Strongbridge Bio
 
Jodi K. Maranchie
Consulting or Advisory Role - Merck; Sanofi
Research Funding - Exelixis (Inst); Janssen (Inst); Merck (Inst)
 
Sarah Joanne Welsh
No Relationships to Disclose
 
Ane Bundsbæk Bøndergaard Iversen
No Relationships to Disclose
 
Ananya Roy
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Yanfang Liu
Employment - Merck
 
Rodolfo F. Perini
Employment - Merck
Stock and Other Ownership Interests - Merck
 
W. Marston Linehan
No Relationships to Disclose
 
Ramaprasad Srinivasan
Research Funding - AstraZeneca (Inst); Calithera Biosciences (Inst); Peloton Therapeutics (Inst); Sanofi (Inst)